|
1
|
Peljto AL, Barker-Cummings C, Vasoli VM,
Leibson CL, Hauser WA, Buchhalter JR and Ottman R: Familial risk of
epilepsy: A population-based study. Brain. 137:795–805. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Brodie MJ, Besag F, Ettinger AB, Mula M,
Gobbi G, Comai S, Aldenkamp AP and Steinhoff BJ: Epilepsy,
antiepileptic drugs, and aggression: An Evidence-Based review.
Pharmacol Rev. 68:563–602. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Kobau R, Cui W, Kadima N, Zack MM,
Sajatovic M, Kaiboriboon K and Jobst B: Tracking psychosocial
health in adults with epilepsy - estimates from the 2010 National
Health Interview Survey. Epilepsy Behav. 41:66–73. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Cui W, Zack MM, Kobau R and Helmers SL:
Health behaviors among people with epilepsy - results from the 2010
National Health Interview Survey. Epilepsy Behav. 44:121–126. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Yang RR, Wang WZ, Snape D, Chen G, Zhang
L, Wu JZ, Baker GA, Zheng XY and Jacoby A: Stigma of people with
epilepsy in China: Views of health professionals, teachers,
employers, and community leaders. Epilepsy Behav. 21:261–266. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Kaiboriboon K, Bakaki PM, Lhatoo SD and
Koroukian S: Incidence and prevalence of treated epilepsy among
poor health and low-income Americans. Neurology. 80:1942–1949.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Marino SE, Birnbaum AK, Leppik IE, Conway
JM, Musib LC, Brundage RC, Ramsay RE, Pennell PB, White JR, Gross
CR, et al: Steady-state carbamazepine pharmacokinetics following
oral and stable-labeled intravenous administration in epilepsy
patients: Effects of race and sex. Clin Pharmacol Ther. 91:483–488.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Hermann B, Seidenberg M, Sager M, Carlsson
C, Gidal B, Sheth R, Rutecki P and Asthana S: Growing old with
epilepsy: The neglected issue of cognitive and brain health in
aging and elder persons with chronic epilepsy. Epilepsia.
49:731–740. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Chen H, Xu G, Du H, Yi M and Li C:
Integrative analysis of gene expression associated with epilepsy in
human epilepsy and animal models. Mol Med Rep. 13:4920–4926. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Berg AT, Baca CB, Loddenkemper T, Vickrey
BG and Dlugos D: Priorities in pediatric epilepsy research:
Improving children's futures today. Neurology. 81:1166–1175. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Puranik YG, Birnbaum AK, Marino SE, Ahmed
G, Cloyd JC, Remmel RP, Leppik IE and Lamba JK: Association of
carbamazepine major metabolism and transport pathway gene
polymorphisms and pharmacokinetics in patients with epilepsy.
Pharmacogenomics. 14:35–45. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Doheny HC, Whittington MA, Jefferys JG and
Patsalos PN: A comparison of the efficacy of carbamazepine and the
novel anti-epileptic drug levetiracetam in the tetanus toxin model
of focal complex partial epilepsy. Br J Pharmacol. 135:1425–1434.
2002. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Kong ST, Lim SH, Lee WB, Kumar PK, Wang
HY, Ng YL, Wong PS and Ho PC: Clinical validation and implications
of dried blood spot sampling of carbamazepine, valproic acid and
phenytoin in patients with epilepsy. PLoS One. 9:e1081902014.
View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Zhou H, Wang N, Xu L, Huang HL and Yu CY:
Clinical study on anti-epileptic drug with B vitamins for the
treatment of epilepsy after stroke. Eur Rev Med Pharmacol Sci.
21:3327–3331. 2017.PubMed/NCBI
|
|
15
|
Ahmed GF, Brundage RC, Marino SE, Cloyd
JC, Leppik IE, Pennell PB, Ramsay RE and Birnbaum AK: Population
pharmacokinetics of unbound and total drug concentrations following
intravenously administered carbamazepine in elderly and younger
adult patients with epilepsy. J Clin Pharmacol. 53:276–284. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Ni G, Qin J, Fang Z, Chen Y, Chen Z, Zhou
J and Zhou L: Increased homocysteine levels in valproate-treated
patients with epilepsy: A meta-analysis. BMJ Open. 4:e0049362014.
View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Sidhu MK, Stretton J, Winston GP, Symms M,
Thompson PJ, Koepp MJ and Duncan JS: Factors affecting
reorganisation of memory encoding networks in temporal lobe
epilepsy. Epilepsy Res. 110:1–9. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Brady CB, Gaziano JM, Cxypoliski RA,
Guarino PD, Kaufman JS, Warren SR, Hartigan P, Goldfarb DS and
Jamison RL: Homocysteine lowering and cognition in CKD: The
Veterans Affairs homocysteine study. Am J Kidney Dis. 54:440–449.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Smeal RM, Stewart KA, Iacob E, Fujinami
RS, White HS and Wilcox KS: The activity within the CA3 excitatory
network during Theiler's virus encephalitis is distinct from that
observed during chronic epilepsy. J Neurovirol. 18:30–44. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Mbuba CK, Ngugi AK, Fegan G, Ibinda F,
Muchohi SN, Nyundo C, Odhiambo R, Edwards T, Odermatt P, Carter JA,
et al: Risk factors associated with the epilepsy treatment gap in
Kilifi, Kenya: A cross-sectional study. Lancet Neurol. 11:688–696.
2012. View Article : Google Scholar : PubMed/NCBI
|
